NASDAQ:PTIX Atrinsic (PTIX) Stock Price, News & Analysis $3.65 -0.05 (-1.35%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Atrinsic Stock (NASDAQ:PTIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atrinsic alerts:Sign Up Key Stats Today's Range$3.46▼$3.8350-Day Range$2.85▼$11.1052-Week Range$2.35▼$15.54Volume212,177 shsAverage Volume567,589 shsMarket Capitalization$2.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Read More… Atrinsic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScorePTIX MarketRank™: Atrinsic scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Atrinsic. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Atrinsic is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atrinsic is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtrinsic has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atrinsic's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.77% of the float of Atrinsic has been sold short.Short Interest Ratio / Days to CoverAtrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atrinsic has recently decreased by 27.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtrinsic does not currently pay a dividend.Dividend GrowthAtrinsic does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.77% of the float of Atrinsic has been sold short.Short Interest Ratio / Days to CoverAtrinsic has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atrinsic has recently decreased by 27.17%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentAtrinsic has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atrinsic this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for PTIX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atrinsic insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Atrinsic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.97% of the stock of Atrinsic is held by institutions.Read more about Atrinsic's insider trading history. Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atrinsic and its competitors with MarketBeat's FREE daily newsletter. Email Address PTIX Stock News HeadlinesProtagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires "100 times more" power. Chip giant AMD's Chief Executive Lisa Su agrees. She declared that the need for more power is already "orders of magnitude higher" than just last year. We believe this exponential increase in energy required to power AI is going to lead to a gold rush in a small set of stocks critical to this push. | Weiss Ratings (Ad)Protagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comProtagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma FirmMay 20, 2025 | msn.comSee More Headlines PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed this year? Atrinsic's stock was trading at $6.86 on January 1st, 2025. Since then, PTIX stock has decreased by 46.8% and is now trading at $3.65. View the best growth stocks for 2025 here. How were Atrinsic's earnings last quarter? Atrinsic Inc. (NASDAQ:PTIX) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($2.75) earnings per share (EPS) for the quarter. When did Atrinsic's stock split? Shares of Atrinsic reverse split on Monday, May 5th 2025.A 1-14 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Atrinsic? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atrinsic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atrinsic investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Heatwurx (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO). Company Calendar Last Earnings5/13/2025Today7/01/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTIX CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-860.52% Return on Assets-354.19% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book1.86Miscellaneous Outstanding Shares590,000Free Float383,000Market Cap$2.15 million OptionableNot Optionable Beta0.36 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:PTIX) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atrinsic Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atrinsic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.